Enjoy complimentary customisation on priority with our Enterprise License!
The hyperkalemia drugs market size is forecast to increase by USD 927.9 million at a CAGR of 20.62% between 2023 and 2028. The market is experiencing significant growth due to the rising prevalence of chronic diseases, particularly diabetes and renal diseases, which are leading causes of hyperkalemia. The market is also driven by the increasing awareness and implementation of essential patient assistance programs, which provide financial assistance to patients in need. Potassium imbalances, or electrolyte issues, disrupt the body's potassium homeostasis and can be caused by chronic kidney disease, congestive heart failure, and other risk factors. However, the poor diagnosis and underreporting of hyperkalemia cases pose a major challenge to market growth. Despite these challenges, the market is expected to expand at a steady pace, driven by the development of new and innovative drugs and the increasing demand for effective treatments for hyperkalemia. Additionally, the growing geriatric population and the increasing prevalence of obesity and metabolic disorders are expected to further fuel market growth. Overall, the Market is poised for robust growth in the coming years, driven by these key trends and challenges.
Hyperkalemia, a condition characterized by elevated potassium levels in the blood, can lead to various health complications such as cardiac arrest and heart failure. The development of the market is driven by the increasing prevalence of chronic hyperkalemia, healthcare costs, and emergency department visits due to the aging population and comorbidities. Strategic alliances among key players like AdvaCare International and the availability of patient assistance programs are expected to boost adoption rates. Treatment options for Hyperkalemia include medications such as Lokelma from ZS Pharma. Customer purchase basket and purchase criteria for these drugs depend on factors like treatment effectiveness, safety, and cost. Other conditions associated with Hyperkalemia include cardiovascular diseases, renal diseases, and metabolic diseases.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The chronic hyperkalemia segment is estimated to witness significant growth during the forecast period. Hyperkalemia, a condition characterized by elevated potassium levels in the blood, can lead to various health complications, including cardiac arrest and heart failure. Potassium imbalances, potassium control, or electrolyte issues are common in individuals with chronic kidney disease and congestive heart failure, as the body's ability to maintain potassium homeostasis is compromised. Risk factors for hyperkalemia include the aging population, comorbidities such as chronic kidney disease, and chronic diseases like diabetes.
Get a glance at the market share of various regions Download the PDF Sample
The chronic hyperkalemia segment was the largest segment and was valued at USD 343.40 million in 2018. The development of strategic alliances among key players in the Market, including AdvaCare International, ZS Pharma, and Vifor Pharma, is driving the growth of this market. The lifecycle of these drugs, customer landscape, and price sensitivity are crucial factors influencing market trends. Chronic hyperkalemia, a significant contributor to healthcare costs, results in frequent emergency department visits. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Hyperkalemia, a condition characterized by elevated potassium levels in the blood, can lead to various health complications including cardiac arrest and heart failure. Potassium imbalances, or electrolyte issues, can disrupt potassium homeostasis and affect individuals with chronic kidney disease, congestive heart failure, and other comorbidities. The development of hyperkalemia is influenced by risk factors such as the aging population, chronic diseases, and certain medications. Hence, such factors are driving the market in North America during the forecast period.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing cases of chronic diseases is notably driving market growth. The Market is experiencing significant growth due to the increasing prevalence of chronic diseases, particularly chronic kidney diseases and cardiovascular disorders. Chronic kidney diseases, which affect over 15% of adults in the US, reduce the kidneys' ability to excrete potassium, increasing the risk of hyperkalemia.
Moreover, this condition can become acute over time, necessitating rapid treatment. RAAS inhibitors, a common class of medicines used to treat diabetes and hypertension, can contribute to hyperkalemia as they increase potassium levels in the body. Thus, such factors are driving the growth of the market during the forecast period.
Patient assistance programs is the key trend in the market. Hyperkalemia, a condition characterized by an excess of potassium in the blood, requires prompt and effective treatment to prevent potential complications. While several approved therapies exist for hyperkalemia, the market for newer drugs, such as Veltassa and Lokelma, is gaining traction due to their superior efficacy.
Moreover, these drugs, although priced higher than their counterparts, are expected to attract a significant portion of the patient population. The high cost, however, can be mitigated through patient assistance programs, which help make these medications more affordable. Thus, such trends will shape the growth of the market during the forecast period.
Poor diagnosis is the major challenge that affects the growth of the market. Hyperkalemia, a condition characterized by an excess of potassium in the blood, can be asymptomatic in its early stages and is often diagnosed through diagnostic tests. Severe cases, however, may present symptoms such as a slow heartbeat and weak pulse.
Moreover, the absence of advanced diagnostic methods for hyperkalemia contributes to the delayed identification of the condition. Currently, a blood test is the only reliable method for diagnosing hyperkalemia. However, false positives can occur due to pseudo-hyperkalemia, a temporary increase in potassium levels caused by electrolyte imbalance. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AdvaCare Pharma: The company offers hyperkalemia drug as relief in antagonizing cardiac toxicity, provided the patient is not receiving digitalis therapy, under the brand name CalcoCare.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Hyperkalemia, a condition characterized by elevated potassium levels in the blood, can lead to various health complications including cardiac arrest and heart failure. Potassium imbalances, or electrolyte issues, are common in chronic kidney disease and congestive heart failure, two major risk factors for hyperkalemia. The development of Hyperkalemia drugs has gained significance due to the increasing prevalence of chronic diseases such as chronic kidney disease, congestive heart failure, and metabolic diseases. Strategic alliances among key players like AdvaCare International, ZS Pharma, and Vifor Pharma are driving the market for Hyperkalemia drugs. The customer landscape for Hyperkalemia drugs is diverse, with varying adoption rates and purchase criteria based on price sensitivity and lifecycle. Chronic hyperkalemia, a long-term condition, requires ongoing treatment, leading to repeat purchases. Customer purchase basket for Hyperkalemia drugs may include medications for comorbidities like cardiovascular diseases and renal diseases. The rising aging population and healthcare costs are also contributing to the growth of the market. Emergency department visits due to hyperkalemia can be costly, making preventive treatments an attractive option. Key players are focusing on developing new therapeutics to address the unmet needs of this patient population. Some of the notable drugs in the market include Lokelma from ZS Pharma and Veltassa from Vifor Pharma. Patient assistance programs are also being implemented to increase the accessibility and affordability of these treatments.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
139 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 20.62% |
|
Market growth 2024-2028 |
USD 927.9 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
16.55 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key countries |
US, Germany, Canada, France, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AdvaCare Pharma, Ardelyx Inc., AstraZeneca Plc, CMP Pharma Inc., CytoSorbents Corp., KVK Tech Inc., LEXINE TECHNOCHEM PRIVATE LTD., Odan Laboratories Ltd., Pfizer Inc., Sanofi SA, Steadfast MediShield Pvt. Ltd., Valens Pharmachem Private Limited, Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market report , market forecast , Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.